SPRO250117P7500
- 0.00
- 0.000.00%
Spero Therapeutics Newsroom
Spero Therapeutics Faces SEC Probe and Leadership Changes
Spero Therapeutics Has Appointed Esther Rajavelu As Interim President And CEO, Stepping In For Sath Shukla, Who Has Agreed To A Voluntary Paid Administrative Leave For An Interim Period, The Board Has Also Appointed Director Frank Thomas As Chairman...
Express News | Spero Therapeutics Inc - Sath Shukla on Voluntary Paid Administrative Leave for Interim Period
Express News | Spero Therapeutics Inc - Cash Runway Guidance Remains Into Mid-2026
Express News | Spero Therapeutics Inc - Frank Thomas Appointed Chairman of the Board
Express News | Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
Press Release: Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
Spero Therapeutics (SPRO) Was Downgraded to a Hold Rating at Evercore ISI
Evercore ISI Group Downgrades Spero Therapeutics to In-Line, Maintains Price Target to $5
Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug
JANX Stock Hits Record High on Prostate Cancer Study Data
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study
H.C. Wainwright Maintains Spero Therapeutics(SPRO.US) With Buy Rating, Maintains Target Price $5
HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $5 Price Target
Buy Rating Reiterated for Spero Therapeutics Amid Promising Trial Progress and Strategic Partnership